Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "gastrointestinal"

123 News Found

SonoScape receives USFDA 510(k) clearance for HD-550 Endoscopy system
Drug Approval | April 18, 2022

SonoScape receives USFDA 510(k) clearance for HD-550 Endoscopy system

The HD-550 endoscopy system has been available outside of the USA since 2019


Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes
Drug Approval | March 29, 2022

Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes

Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults


Dupixent is a star in Sanofi’s immunology strategy
Biotech | March 29, 2022

Dupixent is a star in Sanofi’s immunology strategy

Dupixent peak sales ambition raised to more than €13 billion


Adlarity receives USFDA approval for treatment of Alzheimer
Drug Approval | March 14, 2022

Adlarity receives USFDA approval for treatment of Alzheimer

First and only once-weekly patch for convenient, well-tolerated delivery of most used drug for the treatment of Alzheimer's-related dementia


Indian Pharma Market growth flat in Feb 2022
News | March 09, 2022

Indian Pharma Market growth flat in Feb 2022

Price was the key driver for the period


Serina Fischer appointed GM India at Takeda Pharmaceuticals
People | March 02, 2022

Serina Fischer appointed GM India at Takeda Pharmaceuticals

Serina has over 17 years of experience in the biopharmaceutical industry


Innovent Biologics and AnHeart Therapeutics receive NMPA breakthrough designation for taletrectinib
Biotech | March 01, 2022

Innovent Biologics and AnHeart Therapeutics receive NMPA breakthrough designation for taletrectinib

The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors


Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer
Biotech | January 19, 2022

Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer

These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium


Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra
News | January 12, 2022

Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra

Ind-Ra expects revenue growth of over 12% in 2022.


Pfizer to acquire Arena Pharmaceuticals for US $ 6.7 bn
News | December 14, 2021

Pfizer to acquire Arena Pharmaceuticals for US $ 6.7 bn

The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases